Topiramate as a Treatment for Levodopa-Induced Dyskinesia in Parkinson's Disease

Phase 2 Terminated 20 enrolled University Health Network, Toronto

RandomizedCrossoverDouble-blindTreatment

Summary

A phase II double blind trial to evaluate the effects of the AMPA, glutamte antagonist, topiramate on levodopa-induced dyskinesia in Parkinson's disease

Timeline

Start: 2004-09
Primary completion: —
Completion: 2007-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Topiramate	Small molecule	—	—

Topiramate as a Treatment for Levodopa-Induced Dyskinesia in Parkinson's Disease

Summary

Timeline

Drugs

Indications